Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:
LOGINID/PASSWORD REJECTED

The loginid and/or password sent to STN were invalid.
You either typed them incorrectly, or line noise may
have corrupted them.

Do you wish to retry the logon?
Enter choice (y/N):
Do you wish to use the same loginid and password?
Enter choice (y/N):
Enter new loginid (or press [Enter] for ssspta1617srh):
Enter new password:

LOGINID:
LOGINID:ssspta1617srh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	Jul 15	Data from 1960-1976 added to RDISCLOSURE
NEWS 5	Jul 21	Identification of STN records implemented
NEWS 6	Jul 21	Polymer class term count added to REGISTRY
NEWS 7	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 8	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 9	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 10	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 11	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 12	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 13	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 14	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 15	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 16	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS 17	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS 18	SEP 22	DIPPR file reloaded
NEWS 19	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS 20	SEP 29	DISSABS now available on STN

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:48:48 ON 10 OCT 2003

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:48:56 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    8 OCT 2003  HIGHEST RN 601453-92-3
DICTIONARY FILE UPDATES:   8 OCT 2003  HIGHEST RN 601453-92-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading histamin h3-m2 antagonist generic.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 10:52:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     17 TO ITERATE

100.0% PROCESSED      17 ITERATIONS                          0 ANSWERS
```

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 93 TO 587
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:52:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 367 TO ITERATE

100.0% PROCESSED 367 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> d tot

L3 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 459783-32-5 REGISTRY
CN Methanone, [4-(1,3-benzodioxol-5-ylsulfonyl)phenyl][1'-[(4-butoxyphenyl)methyl][1,4'-bipiperidin]-4-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C35 H42 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 459783-31-4 REGISTRY
CN Methanone, [4-(1,3-benzodioxol-5-ylsulfonyl)phenyl][1'-[[4-[2-(diethylamino)ethoxy]phenyl]methyl][1,4'-bipiperidin]-4-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C37 H47 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 459783-30-3 REGISTRY
CN Methanone, [4-(1,3-benzodioxol-5-ylsulfonyl)phenyl][1'-[[4-[3-(dimethylamino)propoxy]phenyl]methyl][1,4'-bipiperidin]-4-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C36 H45 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel rn l3
E1 THROUGH E3 ASSIGNED

=> fil capl

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.43	155.64

```
FILE 'CAPLUS' ENTERED AT 10:52:38 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Oct 2003  VOL 139 ISS 16
FILE LAST UPDATED: 9 Oct 2003  (20031009/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s e1-3
             1 459783-30-3/BI
             1 459783-31-4/BI
             1 459783-32-5/BI
L4           1 (459783-30-3/BI OR 459783-31-4/BI OR 459783-32-5/BI)

=> d

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:716084  CAPLUS
DN   137:226627
TI   Use of dual H3/M2 antagonists in the treatment of cognition deficit
     disorders
IN   Hey, John A.; Aslanian, Robert G.
PA   Schering Corporation, USA
SO   PCT Int. Appl., 38 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2002072093      A2   20020919       WO 2002-US3975   20020206
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
             ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
             MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
             SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002151565      A1   20021017       US 2002-72340    20020206
PRAI US 2001-267352P    P    20010208


=> fil marpat
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                               6.59      162.23

FILE 'MARPAT' ENTERED AT 10:52:54 ON 10 OCT 2003
```

```
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 139 ISS14)(20030926ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6613905 02 SEP 2003
DE   20300703 21 AUG 2003
EP    1336643 20 AUG 2003
JP 2003243677 29 AUG 2003
WO 2003071559 28 AUG 2003

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1
SAMPLE SEARCH INITIATED 10:52:59 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -     13 TO ITERATE

100.0% PROCESSED      13 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           44 TO      476
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:53:05 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -    356 TO ITERATE

100.0% PROCESSED     356 ITERATIONS                               1 ANSWERS
SEARCH TIME: 00.00.04

L6            1 SEA SSS FUL L1

=> d

L6   ANSWER 1 OF 1  MARPAT  COPYRIGHT 2003 ACS on STN
AN   133:329566  MARPAT
TI   PEGylated interferon-.alpha.-CCR5 antagonist combination HIV therapy
IN   Laughlin, Mark A.
PA   Schering Corporation, USA
SO   PCT Int. Appl., 80 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     --------------    ----  --------       ---------------  --------
PI   WO 2000066141      A2   20001109       WO.2000-US11634  20000501
     WO 2000066141      A3   20010208
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN,
             IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN,
             MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

```
     EP 1175224        A2   20020130       EP 2000-928604   20000501
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
     BR 2000010593     A    20020213       BR 2000-10593    20000501
     JP 2002543144     T2   20021217       JP 2000-615025   20000501
     NZ 514519         A    20030725       NZ 2000-514519   20000501
     NO 2001005367     A    20020103       NO 2001-5367     20011102
PRAI US 1999-304897   19990504
     WO 2000-US11634  20000501


=> fil stng
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   105.51     267.74

FILE 'STNGUIDE' ENTERED AT 10:53:43 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct  3, 2003 (20031003/UP).

=> fil medl capl biosis uspatf
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.48     268.22

FILE 'MEDLINE' ENTERED AT 10:58:43 ON 10 OCT 2003

FILE 'CAPLUS' ENTERED AT 10:58:43 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:58:43 ON 10 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 10:58:43 ON 10 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s histamine
L7       181692 HISTAMINE

=> s H3 antagonist?
L8          620 H3 ANTAGONIST?

=> s cognition deficit or alzheimer
L9       131962 COGNITION DEFICIT OR ALZHEIMER

=> s l8 and l9
L10          24 L8 AND L9

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11          24 DUP REM L10 (0 DUPLICATES REMOVED)

=> d ibib abs 20-24

L11  ANSWER 20 OF 24  USPATFULL on STN
ACCESSION NUMBER:         2000:142126  USPATFULL
TITLE:                    DNA encoding as human histamine receptor of the H3
                          subtype
INVENTOR(S):              Lovenberg, Timothy W., San Diego, CA, United States
```

Erlander, Mark, Encinitas, CA, United States
Huvar, Arne, Santee, CA, United States
Pyati, Jayashree, San Diego, CA, United States
PATENT ASSIGNEE(S): Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6136559		20001024	
APPLICATION INFO.:	US 1998-167354		19981007	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Hamud, Fozia
LEGAL REPRESENTATIVE: Wallen, III, John W.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:411071 CAPLUS
DOCUMENT NUMBER: 127:90515
TITLE: 4-[4'-piperidinyl or 3'-pyrrolidinyl] substituted imidazoles as H3-receptor antagonists, their preparation, and their use in treating cognitive disorders or attention or arousal deficits
INVENTOR(S): Durant, Graham J.; Khan, Amin M.
PATENT ASSIGNEE(S): The University of Toledo, USA
SOURCE: U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 862,657, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5639775	A	19970617	US 1994-313282	19940930
WO 9320061	A1	19931014	WO 1993-US3104	19930331

W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1992-862657 19920401
WO 1993-US3104 19930331
OTHER SOURCE(S): MARPAT 127:90515

AB Piperidinyl or pyrrolidinyl substituted imidazoles and salts thereof, are disclosed which have activity as histamine H3-receptor antagonists. Also disclosed are pharmaceutical compns. and methods of using such compds. for treating cognitive disorder or attention or arousal deficit. Prepn. of compds., e.g. 4-(1-cyclohexylvaleroyl-4-piperidyl)-1H-imidazole, is described.

L11 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:65988 CAPLUS
DOCUMENT NUMBER: 126:99230
TITLE: Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the **H3 antagonist** thioperamide, in models of cognition and cholinergic function
AUTHOR(S): Kirkby, D. L.; Jones, D. N. C.; Barnes, J. C.; Higgins, G. A.
CORPORATE SOURCE: Division Biosciences, University Hertfordshire, Hatfield/Herts, AL10 9AB, UK
SOURCE: Behavioural Pharmacology (1996), 7(6), 513-525
CODEN: BPHAEL; ISSN: 0955-8810
PUBLISHER: Rapid Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study presents a comparison between two inhibitors of acetylcholinesterase, tacrine and E2020 (Donepezil), the 5-HT3 receptor antagonist ondansetron, and the H3 receptor antagonist thioperamide, in models of cholinergic function and cognition in male, Lister hooded rats. The cognitive tests used were an operant VI20 task, the delayed match to position task (short-term memory) and the 5-choice serial reaction time task (attention). Scopolamine (SCOP) (0.075 mg/kg s.c.) was utilized in both the short-term memory and attention tasks to impair performance. Both tacrine (1-30 mg/kg) and E2020 (1-10 mg/kg) similarly produced overt cholinomimetic signs of likely central origin (hypothermia, tremor), although tacrine produced more profound peripheral cholinomimetic signs (miosis, secretory signs) than E2020. Tacrine (30 mg/kg) and E2020 (10 mg/kg) reduced the no. of reinforcements gained in the VI20 schedule. Similarly, both drugs attenuated the SCOP-impairment models in the short-term memory and attention tasks (1-3 mg/kg). Ondansetron (10 ng/kg-1 mg/kg) and thioperamide (0.2-10 mg/kg) failed to elicit overt cholinomimetic signs or influence the no. of food reinforcements gained in the VI20 schedule. Neither ondansetron nor thioperamide attenuated the SCOP-induced impairment in either cognitive task. From the present studies, both E2020 and tacrine showed a similar behavioral profile in the models used, although E2020 was about three times more potent. Furthermore, E2020 but not tacrine appeared to show some discrimination in eliciting central and peripheral cholinomimetic sings. The failure of ondansetron and thioperamide to reverse a SCOP-induced deficit in these models is discussed.

L11 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:700891 CAPLUS
DOCUMENT NUMBER: 121:300891
TITLE: Preparation of imidazole derivatives as histamine **H3 antagonists**
INVENTOR(S): Yanai, Kazuhiko; Watanabe, Takehiko; Gotoh, Tomokazu; Sakashita, Hiroshi; Murakami, Kazuki; Sugiura, Masanori; Fukaya, Chikara
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417058	A1	19940804	WO 1993-JP1822	19931215
W: CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 06271567	A2	19940927	JP 1993-308553	19931116

JP 06271566	A2	19940927	JP 1993-308552	19931116
EP 680960	A1	19951108	EP 1994-903008	19931215
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
PRIORITY APPLN. INFO.:			JP 1993-27145	19930125
			JP 1993-27146	19930125
			WO 1993-JP1822	19931215

OTHER SOURCE(S): MARPAT 121:300891

GI For diagram(s), see printed CA Issue.

AB The invention aims at providing novel compds. having histamine H3 receptor antagonism and relates to compds. represented by general formula (I; m = 4-6; R1 = H, lower alkyl or aralkyl; R2, R3 = H, lower alkyl; R4 H, linear or branched alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl or aralkyl; Z = R5 or AR6; A = S or O; R5 = H, lower alkyl, optionally substituted aryl or aralkyl; R6 = lower alkyl, alkenyl, or alkynyl, or optionally substituted aralkyl), useful as neuroleptics, anticonvulsants, analgesics, for regulation of sleep, eating, body temp., and internal endocritic secretion, as therapeutics for reactivation of brain metab. in the treatment of **Alzheimer**'s diseases, and also as labels for imaging histamine H3 receptor by using positron emission tomog. Thus, .apprx.1 g Raney Ni was added to a soln. of 200 mg thioperamide in EtOH, and stirred for 1 h under ice-cooling. The supernatant liq. was decanted and evapd. under reduced pressure to give a white powder which was dissolved in EtOH followed by adding 5.6 N HCl in EtOH under ice-cooling, stirring the resulting mixt. for 30 min under ice-cooling, and evapg. the solvent in vacuo to give title compd. (II.2HCl). In binding assay using rat cerebral cortex membrane and [3H](R)-.alpha.-methylhistamine, I showed Ki (dissocn. const. for histamine H3 receptor) of 5-200 nM.

L11 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1994:107018 CAPLUS
DOCUMENT NUMBER:	120:107018
TITLE:	Preparation of acylpiperidinylimidazoles and related compounds as histamine **H3 antagonists**.
INVENTOR(S):	Durant, Graham J.; Khan, Amin M.
PATENT ASSIGNEE(S):	University of Toledo, USA
SOURCE:	PCT Int. Appl., 57 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9320061	A1	19931014	WO 1993-US3104	19930331
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9339445	A1	19931108	AU 1993-39445	19930331
EP 633882	A1	19950118	EP 1993-908724	19930331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07509219	T2	19951012	JP 1993-517715	19930331
HU 71353	A2	19951128	HU 1994-2827	19930331
BR 9306190	A	19980623	BR 1993-6190	19930331
US 5633382	A	19970527	US 1994-259926	19940615
US 5639775	A	19970617	US 1994-313282	19940930
NO 9403687	A	19941121	NO 1994-3687	19941003
FI 9404605	A	19941130	FI 1994-4605	19941003
PRIORITY APPLN. INFO.:			US 1992-862657	19920401
			WO 1993-US3104	19930331

OTHER SOURCE(S): MARPAT 120:107018

GI



I



II

AB Title compds. [I; R1 = H, in vivo hydrolyzeable group, alkyl, cycloalkyl, aryl; D = CH2, CH2CH2; Z = S, O; x = 0, 1; n = 0-6; R2 = (substituted) alkyl, carbocyclyl, aryl; with provisos], were prepd. Thus, 4-(4-piperidyl)-1H-imidazole and cyclohexanevaleroyl chloride were heated with dicyclohexylamine in MeCN/CH2Cl2 to give title compd. II. II bound to histamine H3 receptors in rat brain membrane prepns. with IC50 = 4.0 nM. I are claimed for treating narcolepsy, coma, **Alzheimer**'s disease, arousal deficit, and attention deficit.

```
=> s muscarinic antagonist
L12      10065 MUSCARINIC ANTAGONIST

=> s l12 and l9
L13        545 L12 AND L9

=> m2 antagonist
M2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s m2 antagonist?
L14        623 M2 ANTAGONIST?

=> s l14 and l9
L15         85 L14 AND L9

=> dup rem l15
PROCESSING COMPLETED FOR L15
L16         69 DUP REM L15 (16 DUPLICATES REMOVED)

=> d ibib abs 65-69

L16  ANSWER 65 OF 69  USPATFULL on STN
ACCESSION NUMBER:       92:29697  USPATFULL
TITLE:                  Huperzine a analogs as acetylcholinesterase inhibitors
INVENTOR(S):            Kozikowski, Alan P., Ponte Vedre Beach, FL, United
                        States
PATENT ASSIGNEE(S):     Mayo Foundation for Medical Education and Research,
                        Rochester, MN, United States (U.S. corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 5104880               19920414
APPLICATION INFO.:      US 1991-694121           19910501   (7)
```

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shen, Cecilia
LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter & Schmidt
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An acetylcholinesterase inhibitor is provided of the general formula (I): ##STR1## wherein R.sub.1 is H, (C.sub.1 -C.sub.8)alkyl or halo; R.sub.2 is H or (C.sub.1 -C.sub.8)alkyl; R.sub.3 and R.sub.4 are individually H, (C.sub.1 -C.sub.8)alkyl, NO.sub.2, hydroxy or halo; R.sub.5 and R.sub.6 are individually H, (C.sub.1 -C.sub.8)akyl, aryl or aralkyl; R.sub.7 is H, halo or (C.sub.1 -C.sub.8)alkyl, R.sub.8 is halo or (C.sub.1 -C.sub.8)alkyl; R.sub.9 is absent or is H; and the bonds represented by--are individually absent or, together with the adjacent bond, form the unit C.dbd.C, with the proviso that if both of the bonds represented by--are present, R.sub.3 and R.sub.4 cannot both be H unless R.sub.7 or R.sub.8 is halo; and the pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 66 OF 69 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:51648 CAPLUS
DOCUMENT NUMBER: 118:51648
TITLE: Tricyclic compounds as selective muscarinic antagonists: structure activity relationships and therapeutic implications
AUTHOR(S): Eberlein, W. G.; Engel, W.; Hasselbach, K. M.; Mayer, N.; Mihm, G.; Rudolf, K.; Doods, H.
CORPORATE SOURCE: Dep. Pharma Res., Dr. Karl Thomae GmbH, Biberach/Riss, Germany
SOURCE: Pharmacochemistry Library (1992), 18(Trends Recept. Res.), 231-49
CODEN: PHLIDQ; ISSN: 0165-7208
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 34 refs. Pirenzepine, the first M1 selective receptor blocker, exhibits the following selectivity profile: M1 > M4 > M3 > M2. The discovery of this compd., which is currently used in ulcer therapy, gave the impetus for a research project directed towards the development of selective muscarinic antagonists. The availability of muscarinic antagonists with different subtype selectivity offers opportunities for novel therapies. The target profile M1 .gtoreq. M3 .mchgt. M2 has been hypothesized to be suited for the treatment of chronic obstructive airway diseases. The authors were successful in synthesizing compds. displaying hte desired selectivity profile. Compd. AQ-RA 721 has been selected for detailed pharmacol. investigations. Compds. with high affinity to cardiac muscarinic receptors might be useful for the treatment of diseases assocd. with bradycardic disorders. The first compd. of this type, AF-DX 116, has the following selectivity profile: M2 > M4 > M1 > M3. Among the follow-up compds. the most attractive **M2 antagonist** is compd. AQ-RA 741 which exhibits a tenfold higher activity and improved selectivity as compared to AF-DX 116. Exptl. support has accumulated in recent years that selective muscarinic antagonists might exhibit interesting effects on certain functions of the CNS thus leading to new strategies of treating certain symptoms of **Alzheimer**'s disease. Correlation of biol. data with the results of rigorous conformational analyses led to the identification of biol. active conformations corresponding to the selectivity profiles mentioned above.

L16 ANSWER 67 OF 69 USPATFULL on STN
ACCESSION NUMBER: 91:79964 USPATFULL

TITLE: Spiro nitrogen-bridged heterocyclic compounds
INVENTOR(S): Fisher, Abraham, Holon, Israel
Karton, Ishai, Nes Ziona, Israel
PATENT ASSIGNEE(S): Israel Institute for Biological Research, Ness Ziona, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5053412		19911001	
APPLICATION INFO.:	US 1990-507228		19900410	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.
LEGAL REPRESENTATIVE: Darby & Darby
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 2,24
LINE COUNT: 1392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel compounds (I) for treating diseases of the central and peripheral nervous system: ##STR1## including enantiomers, racemates and acid addition and quaternary salts thereof, wherein one of X and Y is O and the other of X and Y is N; Q is (CH.sub.2).sub.n or C(CH.sub.3).sub.2 where n is 1, 2 or 3 and the bridge --Q-- is attached at one end to position 1 and at the other end to position 4 or 5, and R.degree. is hydrogen, methyl or hydroxyl; in the moiety ##STR2## the line connecting Z and Y signifies a double bond when X--Z is O--C--R and Y is N, and a single bond when X--Z is N.dbd.C--R and Y is O; Z is C--R wherein R is selected from hydrogen, NH.sub.2, NH-R" (R"=C.sub.1-6 -alkyl), N(R").sub.2, R", C.sub.2-6 -alkenyl, C.sub.2-6 -alkynyl, C.sub.3-7 -cycloalkyl, R" substituted by hydroxy or by 1-6 halogen atoms, R"O-C.sub.1-6 -alkyl, carboxy-C.sub.1-6 -alkyl, R"OCO-C.sub.1-6 -alkyl, amino-C.sub.1-6 -alkyl, R""NH-C.sub.1-6 -alkyl, (R").sub.2 N-C.sub.1-6 -alkyl, 2-oxo-pyrrolidin-1-ylmethyl, aryl, diarylmethylol, and R" substituted by one or two aryl groups, wherein aryl denotes phenyl optionally substituted by 1-3 halogens, R", R"O and(or) CF.sub.3. Also claimed are compounds wherein the line connecting Z and Y signifies the absence of a bond, X is O, Z is H and Y is NH.sub.2, NO.sub.2 or N.sub.3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 68 OF 69 USPATFULL on STN
ACCESSION NUMBER: 89:65083 USPATFULL
TITLE: Derivatives of quinuclidine
INVENTOR(S): Fisher, Abraham, Holon, Israel
Karton, Ishai, Ness-Ziona, Israel
Heldman, Eliahu, Rehovot, Israel
Levy, Aharon, Moshav Beith Hanan, Israel
Grunfeld, Yona, Rehovot, Israel
PATENT ASSIGNEE(S): State of Israel, represented by Prime Minister's Office, Israel Institute for Biological Research, Ness-Ziona, Israel (non-U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4855290		19890808	
APPLICATION INFO.:	US 1986-853404		19860418	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1985-75166	19850510
	IL 1986-77568	19860110

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bond, Robert T.

LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1,32
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 2093
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Quinuclidine derivatives having the general formula (I) ##STR1## and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR.sup.1 R.sup.2 or two hydrogen atoms; and R.sup.1 and R.sup.2, which may be identical or different, are each alkyl, cyclopentyl, cyclohexyl, aryl, or diarylmethylol, or alkyl which is substituted by one or more aryl groups, or one of R.sup.1 and R.sup.2 may be hydrogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 69 OF 69 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1990:120974 BIOSIS
DOCUMENT NUMBER: BR38:55184
TITLE: EVIDENCE THAT AF-DX-116 A MEMORY FACILITATING MUSCARINIC-**M2 ANTAGONIST** CROSSES THE BLOOD BRAIN BARRIER.
AUTHOR(S): REGENOLD W; PACKARD M G; QUIRION R
CORPORATE SOURCE: DEP. PSYCHIATRY, MCGILL UNIV., DOUGLAS HOSP. RES. CENT., 6875 LA SALLE BLVD., VERDUN, P.Q., CANADA, H4H 1R3.
SOURCE: 19TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PHOENIX, ARIZONA, USA, OCTOBER 29-NOVEMBER 3, 1989. SOC NEUROSCI ABST, (1989) 15 (1), 860.
CODEN: ASNEE5.
DOCUMENT TYPE: Conference
FILE SEGMENT: BR; OLD
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 10:48:48 ON 10 OCT 2003)

FILE 'REGISTRY' ENTERED AT 10:48:56 ON 10 OCT 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 3 S L1 FULL
SEL RN L3

FILE 'CAPLUS' ENTERED AT 10:52:38 ON 10 OCT 2003
L4 1 S E1-3

FILE 'MARPAT' ENTERED AT 10:52:54 ON 10 OCT 2003
L5 0 S L1
L6 1 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 10:53:43 ON 10 OCT 2003

FILE 'MEDLINE, CAPLUS, BIOSIS, USPATFULL' ENTERED AT 10:58:43 ON 10 OCT 2003
L7 181692 S HISTAMINE
L8 620 S H3 ANTAGONIST?
L9 131962 S COGNITION DEFICIT OR ALZHEIMER
L10 24 S L8 AND L9
L11 24 DUP REM L10 (0 DUPLICATES REMOVED)
L12 10065 S MUSCARINIC ANTAGONIST
L13 545 S L12 AND L9
L14 623 S M2 ANTAGONIST?
L15 85 S L14 AND L9
L16 69 DUP REM L15 (16 DUPLICATES REMOVED)

```
=> s l14 and l11
L17          0 L14 AND L11

=> s H3/m2 antagonist
MISSING OPERATOR

=> s (h3 (W) m2) (W) antagonist?
L18          2 (H3 (W) M2) (W) ANTAGONIST?

=> d

L18  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:716084  CAPLUS
DN   137:226627
TI   Use of dual H3/M2 antagonists in the
     treatment of cognition deficit disorders
IN   Hey, John A.; Aslanian, Robert G.
PA   Schering Corporation, USA
SO   PCT Int. Appl., 38 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2002072093      A2   20020919       WO 2002-US3975   20020206
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
             ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
             MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
             SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002151565      A1   20021017       US 2002-72340    20020206
PRAI US 2001-267352P    P    20010208


=> d 2

L18  ANSWER 2 OF 2  USPATFULL on STN
AN     2002:273437  USPATFULL
TI     Use of dual H3/M2 antagonists in the
       treatment of cognition deficit disorders
IN     Hey, John A., Randolph, NJ, UNITED STATES
       Aslanian, Robert G., Rockaway, NJ, UNITED STATES
PA     Schering Corporation (U.S. corporation)
PI     US 2002151565      A1   20021017
AI     US 2002-72340      A1   20020206 (10)
PRAI   US 2001-267352P     20010208 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1363
INCL   INCLM: 514/316.000
NCL    NCLM:  514/316.000
IC     [7]
       ICM: A61K031-4545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> FIL STNGUIDE
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    50.81      319.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE       TOTAL
                                                       ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -3.26       -3.26

FILE 'STNGUIDE' ENTERED AT 11:04:00 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct  3, 2003 (20031003/UP).

=>

---Logging off of STN---


Connection closed by remote host
END

 Unable to generate the STN prompt.
 Exiting the script...
```